Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q4 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $6.41 million versus the consensus estimate of $6.32 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.